Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)

被引：1

作者：

Thiele J. ^{[1
,8
]}

Kvasnicka H.M. ^{[1
]}

Varus E. ^{[1
]}

Kriener S. ^{[3
]}

Engels K. ^{[3
]}

Staib P. ^{[4
]}

Ollig E.S. ^{[1
]}

Griesshammer M. ^{[5
]}

Waller C.F. ^{[6
]}

Pfeifer H. ^{[7
]}

Schmitt-Gräff A. ^{[2
]}

机构：

[1] Institut für Pathologie, Universität Köln

[2] Institut für Pathologie, Universität Freiburg

[3] Institut für Pathologie, Universität Frankfurt

[4] 1. Medizinische Klinik, Universität Köln

[5] 3. Medizinische Klinik, Universität Ulm

[6] Abteilung Hämatologie/Onkologie, Medizinische Klinik, Universität Freiburg

[7] Abteilung Hämatologie, Zentrum Klinische Medizin, Universität Frankfurt

[8] Zentrum für Pathologie, Universität zu Köln, 50924 Köln

来源：

Der Pathologe | 2004年 / 25卷 / 6期

关键词：

Bcr/abl gene; Bone marrow biopsies; Chronic myeloid leukemia; Imatinib mesylate (Gleevec); Leukemic regression; Megakaryocytes;

D O I：

10.1007/s00292-004-0701-x

中图分类号：

学科分类号：

摘要：

In chronic myeloid leukemia following therapy with Imatinib (STI571) hematologic and cytogenetic response is associated with conspicuous changes of bone marrow morphology. However, it is not known to which extent these alterations are accompanied by a loss of the bcr/abl translocation. To study regression of the leukemic cell population we recruited 14 patients lacking pretreatment.Therapy resulted in a reduction ofCD61 + megakaryopoiesis. Dwarf megakaryocytes characteristic for this disorder were replaced by large, normally appearing cells of this lineage. Morphometric analysis confirmed the significant decrease in the number of micromegakaryocytes and yielded planimetric parameters in keeping with normalization. Moreover, a fluorescence in-situ hybridization study in five patients of this cohort revealed that before therapy 70% of all myeloid cells exhibited the bcr/abl gene. Regarding megakaryopoiesis about 65% of the micromegakaryocytes displayed positive signals. Following treatment these bcr/abl + cell populations decreased significantly while the emerging large megakaryocytes lacked a proper labeling. Because cytogenetic response and reduction of atypical micromegakaryocytes are linked, this feature may be useful to monitor therapeutic efficacy.

引用

页码：428 / 435

页数：7

共 41 条

[1]

Amiel A., Yarkoni S., Fejgin M., Et al., Clinical detection of BCR-abl fusion by in situ hybridization in chronic myelogenous leukemia, Cancer Genet Cytogenet, 65, pp. 32-34, (1993)

[2]

Bartl R., Frisch B., Wilmanns W., Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD), Eur J Haematol, 50, pp. 41-52, (1993)

[3]

Beham-Schmid C., Apfelbeck U., Sill H., Et al., Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis, Blood, 99, pp. 381-383, (2002)

[4]

Bentz M., Cabot G., Moos M., Et al., Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization, Blood, 83, pp. 1922-1928, (1994)

[5]

Braziel R.M., Launder T.M., Druker B.J., Et al., Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 Months' experience, Blood, 100, pp. 435-441, (2002)

[6]

Brynes R.K., McCourty A., Ho J.P., Et al., Detection of the Philadelphia chromosome in paraffin-embedded tissue by fluorescence in situ hybridization, Mod Pathol, 7, pp. 565-569, (1994)

[7]

Cervantes F., Hernandez-Boluda J.C., Steegmann J.L., Et al., Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: Results and prognostic factors for response and progression-free survival in 150 patients, Haematologica, 88, pp. 1117-1122, (2003)

[8]

Cordell J.L., Falini B., Erber W.N., Et al., Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes), J Histochem Cytochem, 32, pp. 219-229, (1984)

[9]

Deininger M.W., Cytogenetic studies in patients on imatinib, Semin Hematol, 40, pp. 50-55, (2003)

[10]

Deininger M.W., Goldman J.M., Lydon N., Melo J.V., The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells, Blood, 90, pp. 3691-3698, (1997)

← 1 2 3 4 5 →